Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.

Advanced Solid Tumor Clinical Trial

Official title:

Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic and the Therapeutic Potential of HS-20105 for Injection in Patients With Advanced Solid Tumors.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06144723
• Other study ID #: HS-20105-101
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: March 1, 2024
• Est. completion date: March 1, 2027

Study information

• Verified date: November 2023
• Source: Hansoh BioMedical R&D Company
• Contact: Binghe Xu, PhD
• Phone: 86-10-87788495
• Email: xubinghe[@]csco.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

HS-20105 is a novel antibody-drug conjugate (ADC) targeting Trop-2. This first-in-human trial is aimed to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics (PK), safety and preliminary anti-tumor activity of HS-20105 in patients with advanced solid tumors.

Description:

This is a multicenter, open-label Phase I clinical study evaluating the safety, tolerability, PK, and efficacy of HS-20105 in patients with advanced solid tumors. The study includes Phase Ia (dose escalation) and Phase Ib (dose extension). Phase Ia will conduct a dose escalation using the "Rolling 6" design in advanced solid tumor patients who have failed or are unable to tolerate standard treatment, to evaluate the safety, tolerability, PK characteristics, and efficacy of HS-20105. The subsequent Phase Ib study will be conducted in certain population to evaluate the preliminary efficacy of HS-20105 at different doses and in different populations.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 402
• Est. completion date: March 1, 2027
• Est. primary completion date: March 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men or women aged more than or equal to (=) 18 years.

• Advanced solid tumor patients confirmed by histology or cytology for who that standard treatment is failed or intolerable.

• Patients have at least one target lesion according to RECEST 1.1. The requirements for target lesions are: measurable lesions without local treatment such as irradiation, or with definite progress after local treatment, with the longest diameter = 10 mm in the baseline period (in case of lymph nodes, the shortest axis = 15 mm is required). Patients with only brain and/or bone lesions as target lesions will not be included.

• Fresh or archived tumor tissue samples need to be provided (fresh samples are preferred, and tumor tissue samples within 2 years before the first administration can be accepted; the sample type is formalin fixed, paraffin embedded [FFPE] tumor tissue block or FFPE slides).

• ECOG performance status was 0-1 and did not deteriorate in the previous 2 weeks.

• Estimated life expectancy greater than (>) 12 weeks.

• Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit.

• Females must have the evidence of non-childbearing potential.

• Sign informed consent form.

Exclusion Criteria:

• Has received or is currently undergoing the following treatment:

1. Previously or current treatment with drugs targeting Trop-2 or other ADC drugs conjugated with HS-9265;

2. Received traditional Chinese medicine therapy with anti-tumor indications within 2 weeks prior to the first administration of HS-20105;

3. Received cytotoxic chemotherapy drugs or other anti-tumor system therapies (including endocrine therapy, molecular targeted therapy, or biological therapy) within 3 weeks prior to the first administration of HS-20105;

4. Received macromolecular anti-tumor drugs or experimental drug therapy within 4 weeks before the first administration of HS-20105;

5. Received local radiotherapy within 2 weeks before the first administration of HS-20105; Received more than 30% of bone marrow irradiation or extensive radiation therapy within 4 weeks before the first administration of HS-20105;

6. Received major surgery within 4 weeks before the first administration of HS-20105.

7. Received strong inhibitors or inducers of CYP3A4, CYP2D6, P-gp or BCRP, or drugs with narrow treatment windows for CYP3A4, CYP2D6, P-gp or BCRP sensitive substrates, have been used.

8. Receiving medication that is known to prolong the QT interval or may lead to torsade de pointes.

• Existing abnormal CTCAE = grade 2 resulted from previous treatment.

• History of other malignancy.

• Uncontrolled pleural, ascites or pericardial effusion.

• Known and unstable central nervous system metastases.

• Inadequate bone marrow reserve or serious organ dysfunction.

• Severe, uncontrolled, or active cardiovascular disease.

• Severe or poorly controlled diabetes.

• Severe or poorly controlled hypertension.

• Clinically significant bleeding symptoms within 1 month before the first administration of HS-20105.

• Serious thrombosis events within 3 months before the first administration of HS-20105.

• Serious infection within 4 weeks before the first administration of HS-20105.

• Received continuous glucocorticoid treatment for more than 7 days within 28 days before the first administration of HS-20105.

• Active infectious disease.

• Hepatic encephalopathy, hepatorenal syndrome, or = Child-Pugh B-grade cirrhosis.

• Serious or uncontrolled eye disease.

• Moderate to severe lung diseases that may interfere with the detection or management of drug-related pulmonary toxicity and seriously affect respiratory function.

• Severe neurological or mental disorders that can interfere with assessment.

• Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study.

• History of hypersensitivity to any active or inactive ingredient of HS-20105.

• The subject who is unlikely to comply with study procedures, restrictions, or requirements, judged by the investigator

• The subject whose safety cannot be ensured or study assessments would be interfered, judged by the investigator.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• HS-20105
Administered intravenously every 21 days.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hansoh BioMedical R&D Company

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase Ia: MTD or maximum applicable dose (MAD) of HS-20105	Number of participants with DLT.	Up to12 months.
Primary	Phase Ib: Efficacy of HS-20105	Objective response rate (ORR) according to response evaluation criteria in solid tumors (RECIST) 1.1 by investigator's assessment.	Up to 24 months.
Secondary	Incidence and severity of treatment-emergent adverse events	Incidence of treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.	Up to 36 months.
Secondary	Disease control rate (DCR)	The percentage of patients who have achieved complete response, partial response, and stable disease, according to response evaluation criteria in solid tumors (RECIST) 1.1 by investigator's assessment.	Up to 24 months.
Secondary	Duration of response (DoR)	The time from complete or partial response to disease progression or death, according to response evaluation criteria in solid tumors (RECIST) 1.1 by investigator's assessment.	Up to 24 months.
Secondary	Progression-free survival (PFS)	Progression free survival is defined as the duration of time from study entry to time of progression, death, or is censored at date of last disease assessment.	Up to 24 months.
Secondary	Overall survival (OS)	Overall survival is defined as the duration of time from study entry to death or the date of last contact.	Up to 3 years
Secondary	Maximum plasma concentration (Cmax)	Cmax is defined as maximum observed serum concentration obtained directly from the observed concentration-time data.	Up to 24 months.
Secondary	Time of maximum concentration (Tmax)	Tmax is defined as the time required for a drug to reach peak concentration in plasma.	Up to 24 months.
Secondary	Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t)	Area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration.	Up to 24 months.
Secondary	Elimination half-life (T1/2)	T1/2 is defined as apparent terminal elimination half-life (h).	Up to 24 months.
Secondary	Anti-drug antibodies (ADA) of HS-20105	Number of participants who are positive for ADA will be reported..	Up to 24 months.